Clinical trial · Interventional
Comparison of Intra-operative Radiotherapy With Post-operative Radiotherapy for Women With Ductal Carcinoma in Situ
Comparison of the Efficacy of Intra-operative Radiation Therapy After Conserving Surgery With Post-operative Whole Breast Radiotherapy for Women With Ductal Carcinoma in Situ
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation during surgery followed by external-beam radiation to the entire breast may kill more tumor cells.The clinical trial is conducting to compare the effectiveness of radiation therapy during surgery and whole-breast radiation therapy in treating women who have undergone breast-conversing surgery for Intermediate or high grade ductal carcinoma in situ breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Intraoperative Radiotherapy | Radiation | — | UNRESOLVED |
| Whole breast radiation | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Intraoperative Radiotherapy
- description
- Boost with 20 Gy during BCS, EBRT with 46-50 Gy
- interventionNames
- Radiation: Intraoperative Radiotherapy
- type
- ACTIVE_COMPARATOR
- label
- whole breast radiation
- description
- WRT:whole breast radiation after BCS with 46-50 Gy
- interventionNames
- Radiation: Whole breast radiation
Primary outcomes (2)
- measure
- ipsilateral breast tumor recurrence rate after surgery within five years
- timeFrame
- Within 5 years after surgery
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Tumor diameter \< 5 cm * Intermediate or high grade ductal carcinoma in situ * Informed consent Exclusion Criteria: * No informed consent * Tumor size \> 3,5 cm * Low grade ductal carcinoma in situ * Invasive carcinoma * No indication for a boost
References
Publications (0)
Data not yet available